Preferential binding of IFI16 protein to cruciform structure and superhelical DNA

Biochemical and Biophysical Research Communications

Volumn 422, Issue 4, 2012, Pages 716-720

  Brázda, Václav ^a   Coufal, Jan ^a   Liao, Jack C C ^b   Arrowsmith, Cheryl H ^b  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

DNA binding; IFI16 protein; Protein DNA complex

Indexed keywords

AGAROSE; ALPHA INTERFERON; BRCA1 PROTEIN; CRUCIFORM DNA; DNA BINDING PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN IFI 16; OLIGONUCLEOTIDE; PLASMID DNA; PROTEIN P53; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL MOTILITY; DNA HELIX; DNA SUPERCOILING; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

DNA, CRUCIFORM; DNA, SUPERHELICAL; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; NUCLEIC ACID CONFORMATION; PHOSPHOPROTEINS;

EID: 84862279094     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.065     Document Type: Article

References (43)

1. Luan Y., Lengyel P., Liu C.J. P204, a p200 family protein, as a multifunctional regulator of cell proliferation and differentiation. Cytokine Growth Factor Rev. 2008, 19:357-369.
2. Mondini M., Vidali M., Airo P., De Andrea M., Riboldi P., Meroni P.L., Gariglio M., Landolfo S. Role of the interferon-inducible gene IFI16 in the etiopathogenesis of systemic autoimmune disorders. Ann. N. Y. Acad. Sci. 2007, 1110:47-56.
3. Dawson M.J., Trapani J.A. IFI 16 gene encodes a nuclear protein whose expression is induced by interferons in human myeloid leukemia cell lines. J. Cell Biochem. 1995, 57:39-51.
4. Johnstone R.W., Trapani J.A. Transcription and growth regulatory functions of the HIN-200 family of proteins. Mol. Cell. Biol. 1999, 19:5833-5838.
5. Wenzel M., Wunderlich M., Besch R., Poeck H., Willms S., Schwantes A., Kremer M., Sutter G., Endres S., Schmidt A., Rothenfusser S. Cytosolic DNA triggers mitochondrial apoptosis via DNA damage signaling proteins independently of AIM2 and RNA polymerase III. J. Immunol. 2012, 188:394-403.
6. Hiller S., Kohl A., Fiorito F., Herrmann T., Wider G., Tschopp J., Grutter M.G., Wuthrich K. NMR structure of the apoptosis- and inflammation-related NALP1 pyrin domain. Structure 2003, 11:1199-1205.
7. Trapani J.A., Dawson M., Apostolidis V.A., Browne K.A. Genomic organization of IFI16, an interferon-inducible gene whose expression is associated with human myeloid cell differentiation: correlation of predicted protein domains with exon organization. Immunogenetics 1994, 40:415-424.
8. Liao J.C., Lam R., Brazda V., Duan S., Ravichandran M., Ma J., Xiao T., Tempel W., Zuo X., Wang Y.X., Chirgadze N.Y., Arrowsmith C.H. Interferon-inducible protein 16: insight into the interaction with tumor suppressor p53. Structure 2011, 19:418-429.
9. Kwak J.C., Ongusaha P.P., Ouchi T., Lee S.W. IFI16 as a negative regulator in the regulation of p53 and p21(Waf1). J. Biol. Chem. 2003, 278:40899-40904.
10. Johnstone R.W., Kerry J.A., Trapani J.A. The human interferon-inducible protein, IFI 16, is a repressor of transcription. J. Biol. Chem. 1998, 273:17172-17177.
11. Choubey D., Duan X., Dickerson E., Ponomareva L., Panchanathan R., Shen H., Srivastava R. Interferon-inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity. J. Interferon Cytokine Res. 2010, 30:371-380.
12. Choubey D. DNA-responsive inflammasomes and their regulators in autoimmunity. Clin. Immunol. 2012, 142:223-231.
13. Veeranki S., Choubey D. Interferon-inducible p200-family protein IFI16, an innate immune sensor for cytosolic and nuclear double-stranded DNA: regulation of subcellular localization. Mol. Immunol. 2012, 49:567-571.
14. Egistelli L., Chichiarelli S., Gaucci E., Eufemi M., Schinina M.E., Giorgi A., Lascu I., Turano C., Giartosio A., Cervoni L. IFI16 and NM23 bind to a common DNA fragment both in the P53 and the cMYC gene promoters. J. Cell Biochem. 2009, 106:666-672.
15. Johnstone R.W., Wei W., Greenway A., Trapani J.A. Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. Oncogene 2000, 19:6033-6042.
16. Ouchi M., Ouchi T. Role of IFI16 in DNA damage and checkpoint. Front. Biosci. 2008, 13:236-239.
17. Yan H., Dalal K., Hon B.K., Youkharibache P., Lau D., Pio F. RPA nucleic acid-binding properties of IFI16-HIN200. Biochim. Biophys. Acta 2008, 1784:1087-1097.
18. Jagelska E.B., Brazda V., Pecinka P., Palecek E., Fojta M. DNA topology influences p53 sequence-specific DNA binding through structural transitions within the target sites. Biochem. J. 2008, 412:57-63.
19. Jagelska E.B., Pivonkova H., Fojta M., Brazda V. The potential of the cruciform structure formation as an important factor influencing p53 sequence-specific binding to natural DNA targets. Biochem. Biophys. Res. Commun. 2010, 391:1409-1414.
20. Callejo M., Alvarez D., Price G.B., Zannis-Hadjopoulos M. The 14-3-3 protein homologues from Saccharomyces cerevisiae, Bmh1p and Bmh2p, have cruciform DNA-binding activity and associate in vivo with ARS307. J. Biol. Chem. 2002, 277:38416-38423.
21. Zannis-Hadjopoulos M., Yahyaoui W., Callejo M. 14-3-3 cruciform-binding proteins as regulators of eukaryotic DNA replication. Trends Biochem. Sci. 2008, 33:44-50.
22. Brazda V., Laister R.C., Jagelska E.B., Arrowsmith C. Cruciform structures are a common DNA feature important for regulating biological processes. BMC Mol. Biol. 2011, 12:33.
23. Bates A.D., Maxwell A. DNA topology: topoisomerases keep it simple. Curr. Biol. 1997, 7:R778-R781.
24. Brazdova M., Palecek J., Cherny D.I., Billova S., Fojta M., Pecinka P., Vojtesek B., Jovin T.M., Palecek E. Role of tumor suppressor p53 domains in selective binding to supercoiled DNA. Nucleic Acids Res. 2002, 30:4966-4974.
25. Mazur S.J., Sakaguchi K., Appella E., Wang X.W., Harris C.C., Bohr V.A. Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA involves the C-terminal domain. J. Mol. Biol. 1999, 292:241-249.
26. van Holde K., Zlatanova J. Unusual DNA structures, chromatin and transcription. Bioessays 1994, 16:59-68.
27. Campos J.L., Urpi L., Sanmartin T., Gouyette C., Subirana J.A. DNA coiled coils. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3663-3666.
28. Peter B.J., Ullsperger C., Hiasa H., Marians K.J., Cozzarelli N.R. The structure of supercoiled intermediates in DNA replication. Cell 1998, 94:819-827.
29. Brazda V., Muller P., Brozkova K., Vojtesek B. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity. Biochem. Biophys. Res. Commun. 2006, 351:499-506.
30. Brazda V., Jagelska E.B., Fojta M., Palecek E. Searching for target sequences by p53 protein is influenced by DNA length. Biochem. Biophys. Res. Commun. 2006, 341:470-477.
31. Palecek E., Brazda V., Jagelska E., Pecinka P., Karlovska L., Brazdova M. Enhancement of p53 sequence-specific binding by DNA supercoiling. Oncogene 2004, 23:2119-2127.
32. Kim E., Rohaly G., Heinrichs S., Gimnopoulos D., Meissner H., Deppert W. Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53. Oncogene 1999, 18:7310-7318.
33. Kim E., Deppert W. The versatile interactions of p53 with DNA: when flexibility serves specificity. Cell Death Differ. 2006, 13:885-889.
34. Naseem R., Webb M. Analysis of the DNA binding activity of BRCA1 and its modulation by the tumour suppressor p53. PLoS One 2008, 3:e2336.
35. Brazda V., Jagelska E.B., Liao J.C., Arrowsmith C.H. The central region of BRCA1 binds preferentially to supercoiled DNA. J. Biomol. Struct. Dyn. 2009, 27:97-104.
36. Sarkari F., Sheng Y., Frappier L. USP7/HAUSP promotes the sequence-specific DNA binding activity of p53. PLoS One 2010, 5:e13040.
37. Travers A., Muskhelishvili G. A common topology for bacterial and eukaryotic transcription initiation?. EMBO Rep. 2007, 8:147-151.
38. Naseem R., Sturdy A., Finch D., Jowitt T., Webb M. Mapping and conformational characterization of the DNA-binding region of the breast cancer susceptibility protein BRCA1. Biochem. J. 2006, 395:529-535.
39. Stros M., Bacikova A., Polanska E., Stokrova J., Strauss F. HMGB1 interacts with human topoisomerase IIalpha and stimulates its catalytic activity. Nucleic Acids Res. 2007, 35:5001-5013.
40. Gohler T., Jager S., Warnecke G., Yasuda H., Kim E., Deppert W. Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res. 2005, 33:1087-1100.
41. Muskhelishvili G., Travers A. Transcription factor as a topological homeostat. Front. Biosci. 2003, 8:d279-d285.
42. Brazda V., Palecek J., Pospisilova S., Vojtesek B., Palecek E. Specific modulation of p53 binding to consensus sequence within supercoiled DNA by monoclonal antibodies. Biochem. Biophys. Res. Commun. 2000, 267:934-939.
43. Ma B., Pan Y., Zheng J., Levine A.J., Nussinov R. Sequence analysis of p53 response-elements suggests multiple binding modes of the p53 tetramer to DNA targets. Nucleic Acids Res. 2007, 35:2986-3001.